• Ability to understand the study and willingness to comply with all study procedures by voluntarily signing an informed consent form prior to screening.

• Male or female, 18 years of age or older at the time of signing the informed consent form.

• Patients with chronic liver disease.

• Baseline platelet count ≤ 35 x 109/L prior to enrolment on day 1.

• Proposed elective invasive surgery that meets the following conditions: - Platelet transfusion may be required - Expected to be performed between days 9 and 15 after enrolment - Excludes extremely high-risk surgical operations such as open abdomen, open chest, open skull, and direct cardiac surgery.

• Eastern Collaborative Oncology Group (ECOG) Physical Status (PS) score of 0 or 1.

• According to the researcher, it will be able to fulfil the requirements of this study.

• Male patients who are infertile or who agree to use adequate contraception (including the use of condoms containing spermicides) from the start of screening until completion of the post-treatment phase.

• Female patients who are not menopausal or surgically sterilised need to agree to the use of highly effective contraception (including implants, injectable contraception, combined hormonal contraception \[including vaginal rings\], intrauterine devices, or partner-performed vasectomies) from the start of the screening until the completion of the end-of-treatment phase. The use of barrier contraception with or without spermicide, double barrier contraception and oral contraceptives alone is not adequate.